Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORPBSTC · Entity 144844 | Director | May 22, 2019 | May 24, 2019 |
| Lipocine Inc.LPCN · Entity 7696 | Chief Business Officer | January 26, 2017 | January 30, 2017 |
| Societal CDMO, Inc.REPH · Entity 92137 | Executive VP, Business Dev. | January 02, 2018 | January 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOSPECIFICS TECHNOLOGIES CORP
Report date May 22, 2019 · Filed May 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 376 |
Ending reported balance
After 2019-05-22 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-05-22 · Exercise / conversion · Acquired 15,000 · Balance 15,376 Row 2 · 2019-05-22 · Exercise / conversion · Acquired 3,750 · Balance 19,126 Row 3 · 2019-05-22 · Sale · Disposed 18,750 · Balance 376 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.64 · Expires 2025-04-22 | Direct | 0 |
Reported balance
After 2019-05-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-05-22 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: The options were granted on April 22, 2015 and vested in four equal annual installments beginning on the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2028-03-15 | Direct | 11,250 |
Reported balance
After 2019-05-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-05-22 · Exercise / conversion · Disposed 3,750 · Balance 11,250 F2: The options were granted on March 15, 2018, and vest in four equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on April 22, 2015 and vested in four equal annual installments beginning on the first anniversary of the grant date.
F2: The options were granted on March 15, 2018, and vest in four equal annual installments beginning on the first anniversary of the grant date.
Lipocine Inc.
Report date January 26, 2017 · Filed January 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-01-25 | Direct | 15,000 |
Reported balance
After 2017-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-26 · Grant · Acquired 15,000 · Balance 15,000 F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit
F2: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.
Societal CDMO, Inc.
Report date January 02, 2018 · Filed January 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,500 |
Reported balance
After 2018-01-02 transaction · row 1
1 source rowRow 1 · 2018-01-02 · Grant · Acquired 11,500 · Balance 11,500 F1: All shares of common stock are represented by unvested restricted stock units that will vest in four equal annual installments beginning January 2, 2019, subject to continued employment with the Company. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.04 · Expires 2028-01-02 | Direct | 23,000 |
Reported balance
After 2018-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-02 · Grant · Acquired 23,000 · Balance 23,000 F2: The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of common stock are represented by unvested restricted stock units that will vest in four equal annual installments beginning January 2, 2019, subject to continued employment with the Company. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.
F2: The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2019 Filed May 24, 2019 19:23 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $41.82 | $0.00 |
DisclosureSEC source: 0001062993-19-002408 · form4.xml · derivative · entry 5 Mattila Jyrki · CIK 0001297318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 3,750 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options were granted on March 15, 2018, and vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 22, 2019 Filed May 24, 2019 19:23 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $37.64 | $0.00 |
DisclosureSEC source: 0001062993-19-002408 · form4.xml · derivative · entry 4 Mattila Jyrki · CIK 0001297318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options were granted on April 22, 2015 and vested in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 22, 2019 Filed May 24, 2019 19:23 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 18,750 | $62.06 | $1,163,625.00 |
DisclosureSEC source: 0001062993-19-002408 · form4.xml · nonDerivative · entry 3 Mattila Jyrki · CIK 0001297318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376 Read SEC document |
| May 22, 2019 Filed May 24, 2019 19:23 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionCommon Stock, $0.001 par value | 3,750 | $41.82 | $156,825.00 |
DisclosureSEC source: 0001062993-19-002408 · form4.xml · nonDerivative · entry 2 Mattila Jyrki · CIK 0001297318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 24, 2019 19:23 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionCommon Stock, $0.001 par value | 15,000 | $37.64 | $564,600.00 |
DisclosureSEC source: 0001062993-19-002408 · form4.xml · nonDerivative · entry 1 Mattila Jyrki · CIK 0001297318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 18:26 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $41.82 | $0.00 |
DisclosureSEC source: 0001062993-18-001261 · form4.xml · derivative · entry 1 Mattila Jyrki · CIK 0001297318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: The options were granted on March 15, 2018, and will vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:51 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantEmployee Stock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $9.04 | $0.00 |
DisclosureSEC source: 0001192482-18-000021 · edgar.xml · derivative · entry 2 Mattila Jyrki · CIK 0001297318 · Executive VP, Business Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2028-01-02 F2 · derivative.exercise_date: The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:51 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000021 · edgar.xml · nonDerivative · entry 1 Mattila Jyrki · CIK 0001297318 · Executive VP, Business Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest in four equal annual installments beginning January 2, 2019, subject to continued employment with the Company. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. Read SEC document |
| August 21, 2017 Filed Aug 21, 2017 17:56 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-17-001368 · edgar.xml · derivative · entry 2 Mattila Jyrki · CIK 0001297318 · Executive VP, Business Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning August 21, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. The restricted stock unit award is an inducement grant under NASDAQ listing rule 5635(c)(4). F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning August 21, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. The restricted stock unit award is an inducement grant under NASDAQ listing rule 5635(c)(4). Read SEC document |
| August 21, 2017 Filed Aug 21, 2017 17:56 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001123292-17-001368 · edgar.xml · derivative · entry 1 Mattila Jyrki · CIK 0001297318 · Executive VP, Business Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-08-21 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company. The stock option is an inducement grant under NASDAQ listing rule 5635(c)(4). Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:41 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000129 · doc4_4498.xml · derivative · entry 1 Mattila Jyrki · CIK 0001297318 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 10:50 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $3.61 Strike: $3.61 | $144,400.00 |
DisclosureSEC source: 0001638599-16-001676 · doc4_4385.xml · derivative · entry 1 Mattila Jyrki · CIK 0001297318 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.